Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amicus Therapeutics (FOLD) EBT (2016 - 2025)

Amicus Therapeutics (FOLD) has disclosed EBT for 16 consecutive years, with $3.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, EBT fell 60.39% year-over-year to $3.1 million, compared with a TTM value of $191000.0 through Dec 2025, up 100.66%, and an annual FY2025 reading of $191000.0, up 100.66% over the prior year.
  • EBT was $3.1 million for Q4 2025 at Amicus Therapeutics, down from $34.3 million in the prior quarter.
  • Across five years, EBT topped out at $34.3 million in Q3 2025 and bottomed at -$81.5 million in Q1 2022.
  • Average EBT over 5 years is -$33.1 million, with a median of -$36.1 million recorded in 2023.
  • Peak annual rise in EBT hit 405.14% in 2025, while the deepest fall reached 17860.19% in 2025.
  • Year by year, EBT stood at -$80.3 million in 2021, then rose by 12.72% to -$70.1 million in 2022, then surged by 54.82% to -$31.7 million in 2023, then soared by 125.06% to $7.9 million in 2024, then plummeted by 60.39% to $3.1 million in 2025.
  • Business Quant data shows EBT for FOLD at $3.1 million in Q4 2025, $34.3 million in Q3 2025, and -$19.2 million in Q2 2025.